M&A Deal Summary |
|
|---|---|
| Date | 2019-08-02 |
| Target | Good Choice |
| Sector | E-Commerce |
| Buyer(s) | CVC Capital Partners |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1981 |
| PE ASSETS | 177.0B EUR |
| Size | Mega |
| Type | Sector Agnostic |
CVC Capital Partners is a global private equity firm focused on investments in large companies located in Europe, North America, and Asia. CVC looks for opportunities with stable cash flows and talented management, and will consider businesses in a variety of industries. Target sectors include textiles, industrial products, waste management, building materials, energy/utilities, business services, financial services, distribution, healthcare, media, semiconductors, and gaming. CVC can handle transactions valued from €200 million to €10 billion. CVC Capital Partners was formed in 1981 and is based in Luxembourg.
| DEAL STATS | # |
|---|---|
| Overall | 246 of 328 |
| Sector: E-Commerce M&A | 1 of 2 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 110 of 122 |
| Country: South Korea M&A | 7 of 7 |
| Year: 2019 M&A | 10 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-02 |
Multiversity
Campania, Italy Multiversity is the owner of Italy's largest online university Universitá Telematica Pegaso, as well as Mercatorum University. Pegaso is the largest online university in Italy, offering courses to around 80,000 undergraduate and post-graduate students across more than 70 exam venues. Pegaso's innovative online platform offers a range of programs for the under-served further education market, including bachelor and master degrees, post-graduate masters and single courses. Multiversity was founded in 2006 and is based in Campania, Italy. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-25 |
DFE Pharma
Goch, Germany DFE Pharma is an excipient manufacturer. Excipients are the inactive substances that are blended with the active ingredients in medicine for purposes such as binding, bulking, disintegration or to aid in the processing of the active ingredient. With operations in Europe, India and New Zealand and an active presence in over 100 countries, DFE develops, produces and markets excipients primarily for oral solid dose and dry powder inhalation. DFE Pharma is based in Goch, Germany. |
Buy | - |